BRAF and neoplasm: AXL expression is also correlated with acquired MAPK resistance [29], including BRAFi/MEKi double resistance, and targeting AXL cooperatively inhibited tumor growth with BRAF/MEK inhibitors in patient-derived xenografts [60].